The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Apr. 17, 2020
Applicants:

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Acceleron Pharma, Inc., Cambridge, MA (US);

Inventors:

Paul B. Yu, Boston, MA (US);

Asya Grinberg, Lexington, MA (US);

Dianne S. Sako, Medford, MA (US);

Roselyne Castonguay, Malden, MA (US);

Rita Steeves, Stoneham, MA (US);

Ravindra Kumar, Acton, MA (US);

Assignees:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US);

ACCELERON PHARMA, INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); C07K 14/71 (2006.01); C07K 19/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/179 (2013.01); A61K 47/6811 (2017.08); A61P 9/12 (2018.01); C07K 14/71 (2013.01); C07K 19/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01);
Abstract

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.


Find Patent Forward Citations

Loading…